Spark Gets FDA Greenlight for Luxturna, The First Gene Therapy for Eye Disease Approved in the U.S. Post author:Sam Post published:December 18, 2017 Post category:BioPharma The FDA broke new ground today with a first-of-its-kind therapy for eye disease. Source: BioSpace You Might Also Like <b>Quanta</b> Appoints World Leading Nephrologist To Medical Advisory Board February 5, 2017 ThromboGenics Struggles to Find Patients for Phase II Eye Disease Trial December 7, 2017 ProQR Therapeutics B.V. Appoints As Chief Development Strategy Officer March 26, 2017
